The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...
US-based biotechnology company Seattle Genetics has announced that it has gained the Health Canada's Notice of Compliance with conditions (NOC/c) for marketing its ADCETRIS ((Brentuximab Vedotin)) drug used in treating two lymphoma ...
Tags: Seattle Genetics, ADCETRIS drug, Health Canada's Notice of Compliance